Novel markers of subclinical disease for Ewing family tumors from gene expression profiling

Clinical Cancer Research

Volumn 13, Issue 23, 2007, Pages 6978-6983

  Cheung, Irene Y ^a   Feng, Yi ^a   Danis, Karen ^a   Shukla, Neerav ^a   Meyers, Paul ^a   Ladanyi, Marc ^a   Cheung, Nai Kong V ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHONDROITIN SULFATE PROTEOGLYCAN 5; CYCLIN D1; FAT TUMOR SUPPRESSOR HOMOLOGUE 4 PROTEIN; FIBRONECTIN LEUCINE RICH TRANSMEMBRANE PROTEIN 2; MEMBRANE PROTEIN; PLAKOPHILIN 1; PROTEIN; PROTEOCHONDROITIN SULFATE; SIX TRANSMEMBRANE EPITHELIAL ANTIGEN OF THE PROSTATE 1; TAU PROTEIN; TRANSCRIPTION FACTOR NKX2 2; TRANSMEMBRANE PROTEIN 47; UNCLASSIFIED DRUG; WINGLESS RELATED MMTV INTEGRATION SITE 5A PROTEIN;

ARTICLE; BLOOD SAMPLING; BONE MARROW; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DEVICE; DIAGNOSTIC VALUE; EWING SARCOMA; GENE EXPRESSION PROFILING; HIGH RISK POPULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; MICROARRAY ANALYSIS; MONONUCLEAR CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL;

ADOLESCENT; BONE MARROW; CELL LINE, TUMOR; COHORT STUDIES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE PROTEINS, FUSION; PROGNOSIS; PROTO-ONCOGENE PROTEIN C-FLI-1; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SARCOMA, EWING'S; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 37249020010     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1417     Document Type: Article

References (32)

1. Carvajal R, Meyers P. Ewing's sarcoma and primitive neuroectodermal family of tumors. Hematol Oncol Clin North Am 2005;19:501-25, vi-vii.
2. Foss OP, Brennhovd IO, Messelt OT, Efskind J, Liverud K. Invasion of tumor cells into the blood-stream caused by palpation or biopsy of the tumor. Surgery 1966;59:691-5.
3. de Alava E, Kawai A, Healey JH, et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol 1998;16:1248-55.
4. Peter M, Magdelenat H, Michon J, et al. Sensitive detection of occult Ewing's cells by the reverse transcriptase-polymerase chain reaction. Br J Cancer 1995;72:96-100.
5. West DC, Grier HE, Swallow MM, Demetri GD, Granowetter L, Sklar J. Detection of circulating tumor cells in patients with Ewing's sarcoma and peripheral primitive neuroectodermal tumor. J Clin Oncol 1997;15:583-8.
6. Zoubek A, Ladenstein R, Windhager R, et al. Predictive potential of testing for bone marrow involvement in Ewing tumor patients by RT-PCR: a preliminary evaluation. Int J Cancer 1998;79:56-60.
7. Fagnou C, Michon J, Peter M, et al. Presence of tumor cells in bone marrow but not in blood is associated with adverse prognosis in patients with Ewing's tumor. Societe Francaise d'Oncologie Pediatrique. J Clin Oncol 1998;16:1707-11.
8. Schleiermacher G, Peter M, Oberlin O, et al. Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized Ewing tumor. J Clin Oncol 2003;21:85-91.
9. Yaniv I, Cohen IJ, Stein J, et al. Tumor cells are present in stem cell harvests of Ewings sarcoma patients and their persistence following transplantation is associated with relapse. Pediatr Blood Cancer 2004;42:404-9.
10. Vermeulen J, Ballet S, Oberlin O, et al. Incidence and prognostic value of tumour cells detected by RT-PCR in peripheral blood stem cell collections from patients with Ewing tumour. Br J Cancer 2006;95:1326-33.
11. Lae M, Saito T, Barr F, et al. Expression profiling of pediatric sarcomas with chimeric transcription factors: a study of 153 samples [abstract 1390]. Mod Pathol 2004;17 Suppl 1:330A.
12. Kolb EA, Kushner BH, Gorlick R, et al. Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. J Clin Oncol 2003;21:3423-30.
13. Meyers PA, Krailo MD, Ladanyi M, et al. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J Clin Oncol 2001;19:2812-20.
14. Cheung IY, Cheung NKV. Molecular detection of GAGE expression in peripheral blood and bone marrow: utility as a tumor marker for neuroblastoma. Clin Cancer Res 1997;3:821-6.
15. Cheung IY, Cheung NK. Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR. Clin Cancer Res 2001;7:1698-705.
16. Rodriguez-Galindo C, Liu T, Krasin MJ, et al. Analysis of prognostic factors in Ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital studies. Cancer 2007;110:375-84.
17. Sidransky D. Nucleic acid-based methods for the detection of cancer. Science 1997;278:1054-9.
18. Lindsay MA. Target discovery. Nat Rev Drug Discov 2003;2:831-8.
19. Anzick SL, Trent JM. Role of genomics in identifying new targets for cancer therapy. Oncology 2002;16:7-13.
20. Petricoin EF, Liotta LA. Proteomic approaches in cancer risk and response assessment. Trends Mol Med 2004;10:59-64.
21. Hubert RS, Vivanco I, Chen E, et al. STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci U S A 1999;96:14523-8.
22. Rodeberg DA, Nuss RA, Elsawa SF, Celis E. Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytes. Clin Cancer Res 2005;11:4545-52.
23. Machlenkin A, Paz A, Bar Haim E, et al. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy. Cancer Res 2005;65:6435-42.
24. + T cells. Cancer Immunol Immunother 2006;55:1515-23.
25. Donnellan R, Chetty R. Cyclin D1 and human neoplasia. Mol Pathol 1998;51:1-7.
26. Molenaar JJ, van Sluis P, Boon K, Versteeg R, Caron HN. Rearrangements and increased expression of cyclin D1 (CCND1) in neuroblastoma. Genes Chromosomes Cancer 2003;36:242-9.
27. Baer C, Nees M, Breit S, et al. Profiling and functional annotation of mRNA gene expression in pediatric rhabdomyosarcoma and Ewing's sarcoma. Int J Cancer 2004;110:687-94.
28. Cheung IY, Feng Y, Vickers A, Gerald W, Cheung NK. Cyclin D1, a novel molecular marker of minimal residual disease, in metastatic neuroblastoma. J Mol Diagn 2007;9:237-41.
29. Staege MS, Hutter C, Neumann I, et al. DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets. Cancer Res 2004;64:8213-21.
30. Smith R, Owen LA, Trem DJ, et al. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell 2006;9:405-16.
31. Papagerakis S, Shabana AH, Depondt J, Gehanno P, Forest N. Immunohistochemical localization of plakophilins (PKP1, PKP2, PKP3, and p0071) in primary oropharyngeal tumors: correlation with clinical parameters. Hum Pathol 2003;34:565-72.
32. Christophe-Hobertus C, Szpirer C, Guyon R, Christophe D. Identification of the gene encoding brain cell membrane protein 1 (BCMP1), a putative four-transmembrane protein distantly related to the peripheral myelin protein 22/epithelial membrane proteins and the claudins. BMC Genomics 2001;2:3.